Aegera Therapeutics INC.
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia AML
Published in Blood Weekly, December 3rd, 2009
The study, entitled "An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen", is being conducted in the United States and Canada and will also be conducted in Germany, subject to final regulatory approval. This clinical trial follows shortly after the completion of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2009-12-03)
More Articles from Blood Weekly
- University of Minnesota
U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence - American Heart Association
American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis - American Heart Association
American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI - American Heart Association
American Heart Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular Disease Patients With Diabetes and Kidney Disease - American Heart Association
American Heart Association Late-Breaking Clinical Trial Report: Study Finds no Significant Cardiovascular Differences Between More Aggressive or Restrictive Post-Operative Treatment of Anemia - AstraZeneca
Results From Two Phase II Trials Add to Understanding of Ticagrelor BRILINTA and How it Works in the Body - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
